Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Gains from Sales and Divestitures: 2022-2025

Historic Gains from Sales and Divestitures for bioAffinity Technologies (BIAF) over the last 2 years, with Sep 2025 value amounting to $5,628.

  • bioAffinity Technologies' Gains from Sales and Divestitures fell 94.11% to $5,628 in Q3 2025 from the same period last year, while for Sep 2025 it was $5,628, marking a year-over-year decrease of 94.11%. This contributed to the annual value of $31,973 for FY2024, which is 45.86% down from last year.
  • Per bioAffinity Technologies' latest filing, its Gains from Sales and Divestitures stood at $5,628 for Q3 2025, which was down 96.74% from $172,660 recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' Gains from Sales and Divestitures ranged from a high of $172,660 in Q2 2025 and a low of $5,628 during Q3 2025.
  • For the 3-year period, bioAffinity Technologies' Gains from Sales and Divestitures averaged around $59,374, with its median value being $45,512 (2023).
  • Data for bioAffinity Technologies' Gains from Sales and Divestitures shows a peak YoY increase of 2,422.06% (in 2025) and a maximum YoY decrease of 94.11% (in 2025) over the last 5 years.
  • Over the past 4 years, bioAffinity Technologies' Gains from Sales and Divestitures (Quarterly) stood at $29,728 in 2022, then spiked by 98.64% to $59,051 in 2023, then slumped by 45.86% to $31,973 in 2024, then slumped by 94.11% to $5,628 in 2025.
  • Its last three reported values are $5,628 in Q3 2025, $172,660 for Q2 2025, and $92,601 during Q1 2025.